Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02905331 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
A Phase 3 study of Psoriasis, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
- 14
- Study locations
NCT02905331: Completed Phase 3 study of Psoriasis, sponsored by Janssen Research & Development.
NCT02905331 is a Phase 3 study of Psoriasis that has completed, run by Janssen Research & Development. The registered enrollment target is 78 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (84% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02905331, a Phase 3 study of Psoriasis, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type psoriasis.
Primary Outcome
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) or minimal (1) were considered IGA cleared or minimal responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failu
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Guselkumab
Study Locations (14)
Other
- Niepubliczny Zaklad Opieki Zdrowotnej Osteo-Medic s.c. Artur Racewicz i Jerzy Supronik - Bialystok
- Szpital Uniwersytecki nr 1 im Dr A Jurasza - Bydgoszcz
- Wromedica Irena Bielicka, Janusz Szczepanik S.C. - Wroclaw
Ontario
- Dermatrials Research - Hamilton
- DermEdge Research - Mississauga
Florida
- Renstar Medical Research - Ocala
Illinois
- Arlington Dermatology - Rolling Meadows
Indiana
- Indiana Clinical Trial Center - Plainfield
Kentucky
- Dermatology Specialists - Louisville
Michigan
- Hamzavi Dermatology - Fort Gratiot
Pennsylvania
- University of Pittsburgh Department of Dermatology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2018-02-06 |
| Phase | Phase 3 |
What the finished NCT02905331 record still lists
NCT02905331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02905331 lists 14 locations in 11 states (Other, Ontario, Florida).
Frequently Asked Questions
What is clinical trial NCT02905331 about?
NCT02905331 is a clinical study titled "Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis". The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type psoriasis.
What is the current status of trial NCT02905331?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2017-02-28. Estimated completion is 2018-02-06.
What conditions does trial NCT02905331 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02905331?
The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT02905331?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02905331 being conducted?
This trial has 14 study locations across Florida, Illinois, Indiana, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02905331's enrollment target sits among peer trials
78 64th of 125 higher than 62 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI